BAM conditioning before autologous transplantation for lymphoma: a study on behalf of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)

Cornillon, Jérôme; Daguenet, Élisabeth; Bay, Jacques‐Olivier; Chauchet, Adrien; Salles, Gilles; Contentin, Nathalie; Nicolas‐Virelizier, Emmanuelle; Mercier, Mélanie; Vallet, Nicolas; Alexis, Magda; Chrétien, Marie‐Lorraine; Cluzeau, Thomas; Huynh, Anne; Himberlin, Chantal; Dorvaux, Véronique; Amorim, Sandy; Lejeune, Caroline; Latour, Régis Peffault de; Gyan, Emmanuel

doi:10.1007/s00277-019-03704-z

Ann Hematol

2019

DOI: 10.1007/s00277-019-03704-z

|View full text |Cite

BAM conditioning before autologous transplantation for lymphoma: a study on behalf of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)

Jérôme Cornillon

Élisabeth Daguenet

Jacques‐Olivier Bay

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2019

2021

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Busulfan/cytarabine/melphalan

2019

Reactions Weekly

View full text Add to dashboard Cite

Busulfan/cytarabine/melphalan Respiratory distress syndrome: case reportIn a retrospective study of 177 patients, who received conditioning treatment before autologous haematopoietic stem cell transplantation (ASCT) between 2000 and 2015, an adult patient [sex and exact age not stated] was described, who developed respiratory distress syndrome during treatment with busulfan, cytarabine and melphalan [routes and dosages not stated].The patient had lymphoma, and ASCT was scheduled. The patient received conditioning therapy with busulfan, cytarabine [aracytine] and melphalan, and the patient underwent the ASCT. The patient developed toxicity in the form of respiratory distress syndrome secondary to busulfan, cytarabine and melphalan, and died within 100 days from the ASCT [duration of treatment to reaction onset not stated].

show abstract

Busulfan/cytarabine/melphalan

2019

Reactions Weekly

View full text Add to dashboard Cite

show abstract

Allogeneic hematopoietic cell transplantation using fludarabine plus myeloablative busulfan and melphalan confers promising survival in high-risk hematopoietic neoplasms: a single-center retrospective analysis

et al. 2021

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

BAM conditioning before autologous transplantation for lymphoma: a study on behalf of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)

Cited by 2 publications

References 18 publications

Busulfan/cytarabine/melphalan

Busulfan/cytarabine/melphalan

Allogeneic hematopoietic cell transplantation using fludarabine plus myeloablative busulfan and melphalan confers promising survival in high-risk hematopoietic neoplasms: a single-center retrospective analysis

Contact Info

Product

Resources

About